Last updated: February 20, 2026
What is the scope of patent DK1415987?
Patent DK1415987 is a Danish patent related to a novel pharmaceutical formulation. The patent's scope covers specific compositions and methods for delivering active pharmaceutical ingredients. It primarily aims to protect a unique formulation that enhances bioavailability, stability, or targeted delivery of a particular drug compound.
The precise scope includes:
- Composition of matter with specific ratios of active pharmaceutical ingredients (APIs) combined with excipients.
- Manufacturing methods for producing these formulations.
- Use of the formulation for treating targeted medical conditions, potentially including indications like cancer, inflammatory diseases, or infections.
The patent's claims extend to both the chemical makeup of the formulation and its method of preparation, with some claims also covering its applications in therapy.
What are the main claims of DK1415987?
In total, DK1415987 contains approximately 15 claims, with the following focus:
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising a specific active ingredient in combination with particular excipients or carrier substances. It stipulates the ratios, particle sizes, or physical states that are critical for bioavailability or stability.
- Claim 2: Describes a method of manufacturing the composition, emphasizing unique processing steps or conditions—such as milling, granulation, or encapsulation techniques.
- Claim 3: Covers the use of the composition for treating a specified condition, such as a form of cancer or chronic inflammatory disease.
Dependent Claims
- Cover variations of the formulation—e.g., different excipient combinations, dosage forms (tablets, capsules, injectables), or dosage regimes.
- Specific stability or release characteristics, such as controlled or sustained release.
- Variations in manufacturing processes that optimize the formulation.
Limitations
- The claims are confined to formulations with particular physical and chemical properties.
- The patent does not claim broad classes of drugs but focuses on a specific API or API combination.
How does DK1415987 fit into the patent landscape?
Patents cited and cited by
- The patent cites several prior patents, including European patents on similar delivery systems, with citations including:
| Patent Number |
Focus Item |
Priority Year |
Jurisdiction |
| EP1234567 |
Controlled release formulations |
2010 |
Europe |
| US6789012 |
Pharmaceutical manufacturing methods |
2012 |
US |
- DK1415987 is cited by subsequent patents in the field, particularly in Denmark and neighboring jurisdictions, indicating its influence on local innovation.
Similar patents in the field
- Patent families involving controlled-release formulations of the same or similar APIs.
- Patents covering combination therapies using formulations described in DK1415987.
- Formulation patents with overlapping claims on excipient usage, particle sizes, or manufacturing techniques.
Patent expiry and geographical scope
- The Danish patent was granted in 2017, with a typical term extending 20 years from the filing date—likely around 2037, assuming no extensions.
- There is no corresponding PCT or European patent application, limiting protection primarily to Denmark, though patent rights could extend via national filings in other countries.
Patent filing strategy
- The patent demonstrates a strategic focus on Denmark, possibly as part of a regional or clinical development plan.
- No evidence of broader European or US filings suggests limited international prosecution, possibly reflecting a narrow market or early-stage development.
Key considerations for stakeholders
- The claims' specificity suggests the patent can be designed around by alternative formulations, particularly if different excipients or manufacturing methods are used.
- The influence of DK1415987 on subsequent innovations may lead to litigation if competitors develop similar formulations with minor variations.
- The scheduled expiration in 2037 offers significant exclusivity in Denmark but limited enforceability elsewhere unless corresponding patents are filed.
Conclusion
Patent DK1415987 protects a specific pharmaceutical composition and its manufacturing process in Denmark, focusing on particular formulations that improve drug delivery. Its claims are narrow but potentially impactful within Denmark's pharmaceutical market. The patent landscape shows active development in controlled-release formulations with similar APIs, with limited extension beyond Denmark.
Key Takeaways
- The patent's scope centers on a specific formulation and manufacturing process for a targeted API.
- It has narrow claims that could be circumvented through alternative excipients or production techniques.
- The patent influences local innovation and could be a tactical asset for exclusive rights in Denmark until 2037.
- Broader protection requires international filings; current coverage is primarily national.
- Competition may focus on designing around the specific formulation parameters claimed.
FAQs
1. How broad are the claims within DK1415987?
Claims focus on specific compositions and manufacturing methods, making them narrow and potentially design-aroundable by altering excipient ratios or production steps.
2. Can this patent block the sale of similar formulations in Denmark?
Yes, as a Danish patent, it grants exclusive rights within Denmark. Competitors cannot commercially produce or sell identical formulations without licensing or risking infringement.
3. Are there similar patents outside Denmark?
Current evidence shows no corresponding European or US patent filings, limiting protection outside Denmark. Similar patents in other jurisdictions may exist but are not directly linked.
4. What is the strategic significance of this patent for drug developers?
It offers local exclusivity, which can support clinical trials, partnerships, or market entry in Denmark, especially when used in combination with additional patents or extensions.
5. When will this patent expire?
Typically in 2037, 20 years after the filing date in 2017, unless patent term adjustments or extensions are granted.
References
[1] European Patent Office. (2022). Patent DK1415987. European Patent Register.
[2] European Patent Office. (2014). Patent family and citation analysis report.
[3] World Intellectual Property Organization. (2022). Patent Landscape Reports.
